Supreme Court Refuses Ephedra Case, Battle Against Risk-Benefit Continues
This article was originally published in The Tan Sheet
Executive Summary
Challenges to the risk-benefit analysis FDA applied in banning the use of ephedra will continue following the Supreme Court's May 14 refusal to hear Nutraceutical Corp.'s appeal, according to the firm's attorney and to industry trade groups
You may also be interested in...
Kratom Action Presents Regulatory Puzzle For FDA
The agency is seizing imports of kratom but industry seeks to clarify whether the substance, which in large doses can have narcotic effects, can be used in dietary supplements. Because FDA acknowledges kratom is a dietary ingredient, a ban as used for ephedra action may be up for consideration.
Kratom Action Presents Regulatory Puzzle For FDA
The agency is seizing imports of kratom but industry seeks to clarify whether the substance, which in large doses can have narcotic effects, can be used in dietary supplements. Because FDA acknowledges kratom is a dietary ingredient, a ban as used for ephedra action may be up for consideration.
FDA Ushers Out Known DMAA, Closes Dietary Ingredient Door
USPlabs says it will reformulate its DMAA supplements, although it “stands by the safety and legality” of the products. FDA says “credible science” shows DMAA is not a botanical, not a dietary ingredient and will not be accepted in an NDI notification.